Novel 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor

Abstract

The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

1 . A method for identifying a compound capable of treating a bone-associated disorder, comprising: 
 (a) contacting a polypeptide which comprises the amino acid sequence of SEQ ID NO:11 with a test compound;    (b) assaying the ability of the test compound to modulate the carboxypeptidase activity of the polypeptide, thereby identifying a compound capable of treating a bone-associated disorder.    
     
     
         2 . A method for identifying a compound capable of modulating a bone cell activity comprising: 
 (a) contacting a bone cell with a test compound;    (b) assaying the ability of the test compound to modulate the expression or carboxypeptidase activity of a polypeptide comprising the amino acid sequence of SEQ ID NO:11, thereby identifying a compound capable of modulating a bone cell activity.